Novel artificial intelligence-enabled deep learning system to enhance adenoma detection: a prospective randomized controlled study

新型人工智能深度学习系统提升腺瘤检出率:一项前瞻性随机对照研究

阅读:1

Abstract

BACKGROUND AND AIMS: Several artificial intelligence (AI) systems for polyp detection during colonoscopy have emerged in the gastroenterology literature and continue to demonstrate significant improvements in quality outcomes. This study assesses clinical quality outcomes during white-light colonoscopy with and without a novel AI computer-aided detection system, DEtection of Elusive Polyps (DEEP(2)), using Fuji 7000 series colonoscopes (Fujifilm, Singapore). METHODS: An unblinded, randomized (1:1), controlled, prospective study was performed at a single ambulatory care endoscopy center under institutional review board approval. Included participants ages 40 to 85 years were scheduled to undergo colonoscopy for screening, surveillance, or symptoms. Exclusion criteria were inflammatory bowel disease, prior colorectal surgery, known polyp referral, pregnancy, inadequate bowel prep, and incomplete colonoscopies. DEEP(2) was trained and validated only on white-light imaging, excluding the use of continuous digital chromoendoscopy. RESULTS: Mean patient age was 62.4 years (SD, 10.29), and 49% were men. Of 674 colonoscopies analyzed, significant differences were found in the adenoma detection rate (ADR) between the 2 arms of the study, those performed without versus with DEEP(2) (10% vs 27%-37%, respectively; P = .0057). Significant differences were also found for adenomas per colonoscopy (APCs; .62 vs .39, respectively; P < .001) and polyp detection rate (17% vs 39%-56%, respectively; P < .001). In the right-sided colon, where most interval cancers are found, it also showed significant ADR and APC differences (P < .01). The false alert rate (mean, 4 per examination) was lower than the mean of >20 false alerts reported for other computer-aided detection systems. Withdrawal times were equivalent between arms (mean, 7.2 minutes; not significant). CONCLUSIONS: Seven enrolled physicians and 5 participating nurses reported a unanimous desire to continue using DEEP(2) after the completion of the study and after commercial availability. (Clinical trial registration number: MYTRIALS.).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。